REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants
Rhea-AI Summary
REGENXBIO (Nasdaq: RGNX) priced an underwritten public offering of 10,003,889 common shares at $9.00 per share and 1,111,111 pre-funded warrants at $8.9999 per warrant, before underwriting discounts and commissions. Expected gross proceeds are approximately $100 million, excluding the underwriters’ option.
The offering is expected to close on July 20, 2026, subject to customary conditions. REGENXBIO granted underwriters a 30-day option to buy up to an additional 1,667,250 common shares. Morgan Stanley, J.P. Morgan, Leerink Partners and Mizuho are joint book-running managers.
Positive
- ~$100 million expected gross proceeds from equity and warrant offering
- Underwriters granted 30-day option for 1,667,250 additional shares
- Offering terms set with common at $9.00 and warrants at $8.9999
Negative
- Issuance of 10,003,889 new common shares in public offering
- Sale of 1,111,111 pre-funded warrants adds additional future share supply
News Explained
If it closes, REGENXBIO will receive gross proceeds while common issuance and warrant conversion can reduce existing ownership percentages.
The July 17 release reports a priced underwritten offering, not a completed sale: REGENXBIO would receive the stated gross proceeds, while issuing common shares and potentially shares on warrant exercise can reduce existing holders’ percentage ownership if the offering closes.
The pre-funded warrants are priced near the full share price and have a nominal exercise price, converting into shares when exercised; the release separately states that closing is expected on
The first-quarter report showed
Form S-3 provides registration capacity for future sales rather than selling shares by itself, and the final prospectus supplement is the specified checkpoint for the offering’s final terms.
Sources and calculations
- REGENXBIO pricing release (2026-07-17)
- Dilution definition (2026-07-14)
- Pre-funded warrant definition (2026-07-14)
- Form S-3 purpose (2026-07-14)
- Prospectus supplement purpose (2026-07-14)
- REGENXBIO first-quarter 2026 report (2026-03-31)
- Cash and equivalents vs quarterly operating cash outflow, in days of cash use $15,229,000 / ($76,186,000 / 90) = [object Object]
News Market Reaction – RGNX
In the Jul 17 session, RGNX declined 11.70%, reflecting a significant negative market reaction. Argus tracked a peak move of +4.9% during that session. Argus tracked a trough of -10.1% from its starting point during tracking. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility. Trading volume was above average at 1.6x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 29 | Milestone payment | Positive | +12.9% | AbbVie milestone triggered by first patient dosing in NAAVIGATE DR trial. |
| Jun 24 | Clinical program update | Positive | +0.2% | Completion of RGX-202 confirmatory study supporting planned BLA submission. |
| Jun 22 | FDA alignment | Positive | +18.2% | Agreement with FDA on NAVSUNLI BLA resubmission path for accelerated approval. |
| May 18 | Conference participation | Neutral | -1.1% | Announcement of participation in upcoming investor conferences. |
| May 14 | Earnings report | Negative | -37.8% | Q1 2026 results with lower revenue and significant net loss. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
RGNX has generally risen on positive clinical and regulatory milestones but sold off sharply on its last earnings report.
Key Terms
underwritten public offering financial
pre-funded warrants financial
registration statement on form s-3 regulatory
prospectus supplement regulatory
joint book-running managers financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Morgan Stanley, J.P. Morgan, Leerink Partners and Mizuho are acting as joint book-running managers of the offering.
The securities described above are being offered by REGENXBIO pursuant to a Registration Statement on Form S-3 that was filed with the Securities and Exchange Commission (the "SEC") on November 26, 2025 (File No. 333-291816) and declared effective on December 12, 2025. A preliminary prospectus supplement relating to and describing the terms of the offering was filed with the SEC and is available on the SEC's website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering, when available, may be obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor,
This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the applicable securities laws of such state or jurisdiction.
ABOUT REGENXBIO Inc.
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie, and NAVSUNLI™ (clemidsogene lanparvovec-sngl, RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people.
FORWARD-LOOKING STATEMENTS
This press release includes "forward-looking statements," within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements express a belief, expectation or intention and are generally accompanied by words that convey projected future events or outcomes such as "anticipate," "assume," "believe," "continue," "could," "design," "estimate," "expect," "forecast," "goal," "intend," "may," "objective," "plan," "position," "potential," "predict," "project," "seek," "should," "will," "would" or variations of such words or by similar expressions. The forward-looking statements include statements relating to, among other things, statements regarding the timing and success of the proposed offering and whether REGENXBIO will be able to raise capital through the sale of shares of common stock. REGENXBIO has based these forward-looking statements on its current expectations and assumptions and analyses made by REGENXBIO in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors REGENXBIO believes are appropriate under the circumstances. However, whether actual results and developments will conform with REGENXBIO's expectations and predictions is subject to a number of risks and uncertainties, including the timing of enrollment, commencement and completion and the success of clinical trials conducted by REGENXBIO, its licensees and its partners, the timing of commencement and completion and the success of preclinical studies conducted by REGENXBIO and its development partners, the timely development and launch of new products, the ability to obtain and maintain regulatory approval of product candidates, the ability to obtain and maintain intellectual property protection for product candidates and technology, trends and challenges in the business and markets in which REGENXBIO operates, the size and growth of potential markets for product candidates and the ability to serve those markets, the rate and degree of acceptance of product candidates, and other factors, many of which are beyond the control of REGENXBIO. Refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of REGENXBIO's Annual Report on Form 10-K for the year ended December 31, 2025, and comparable "Risk Factors" sections of REGENXBIO's Quarterly Reports on Form 10-Q and other filings, which have been filed with the U.S. Securities and Exchange Commission (the "SEC") and are available on the SEC's website at www.sec.gov. All of the forward-looking statements made in this press release are expressly qualified by the cautionary statements contained or referred to herein. The actual results or developments anticipated may not be realized or, even if substantially realized, they may not have the expected consequences to or effects on REGENXBIO or its businesses or operations. Such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Readers are cautioned not to rely too heavily on the forward-looking statements contained in this press release. These forward-looking statements speak only as of the date of this press release. Except as required by law, REGENXBIO does not undertake any obligation, and specifically declines any obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
ZOLGENSMA® is a registered trademark of Novartis. All other trademarks referenced herein are registered trademarks of REGENXBIO.
CONTACTS:
Dana Cormack
Corporate Communications
Dcormack@regenxbio.com
Investors:
George E. MacDougall
Investor Relations
IR@regenxbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-announces-pricing-of-public-offering-of-common-stock-and-pre-funded-warrants-302828273.html
SOURCE REGENXBIO Inc.